ClinicalTrials.gg
CompletedNCT02464046Updated Apr 27, 2025

Study to Evaluate Efficacy, Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder Without Psychiatric Comorbidity

A Phase 2 interventional study of JNJ-42847922 and Placebo in Insomnia, sponsored by Janssen Research & Development, LLC. Completed at 5 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2015, 10 years 11 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jul 2016.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Sleep Initiation and Maintenance Disorders with a site in Germany — 4 open to participants now, 4 under way, 1 of them phase 3. Sleep Initiation and Maintenance Disorders · Germany.

Enrollment
41st of 47
28 · median 89
Started
2015
the only one that year
Phase 2
11 of 50
none open now
Registered
20th of 50
by date
Lead sponsor
3 of 50
Janssen Research & Development, LLC

Among the 50 studies in Sleep Initiation and Maintenance Disorders with a site in Germany, this one is the 41st largest by enrollment of the 47 interventional ones that give a count, is the only one that started in 2015, is one of 11 in phase 2, and was the 20th registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

4 of the 50 studies in Sleep Initiation and Maintenance Disorders with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Sleep Initiation and Maintenance Disorders with a site in Germany, or all of them as a file.
02

Study summary

The primary purpose of this study is to investigate the effect of JNJ-42847922 (change versus placebo) on sleep efficiency (SE) measured by polysomnography (PSG) after single and multiple dose administration to participants with insomnia disorder without psychiatric comorbidity.

Read the detailed description

This is a multi-center, randomized (study medication assigned to participants by chance), placebo-controlled, double-blind (neither physician nor participant knows the identity of the assigned treatment), 2-way cross-over study of JNJ-42847922 participants with insomnia disorder without psychiatric comorbidity. The study consists of following phases: screening (28 days prior to Day 1), a double-blind treatment phase (consists of 5-day treatments, either JNJ-42847922 or placebo in subsequent 2-treatment periods, each separated with washout period of 5 to 9 days), and a follow-up examination (7 to 14 days after last dose administration). Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Insomnia

Keywords

  • Insomnia
  • JNJ-42847922
  • Placebo
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female participants aged between 18 and 65 years, inclusive
  • (BMI) between 18 and 30 kilogram per square meters (kg/m\^2) inclusive (BMI = weight/height\^2)
  • Insomnia Severity Index (ISI) score more than or equal to (>=) 15 at screening
  • Insomnia: at screening participants will report both difficulties with sleep onset and sleep maintenance. Insomnia will furthermore objectively be established prior to enrollment per PSG recorded over 3 consecutive nights. Participants will sleep for 3 consecutive nights in the sleep center. First and second night data will be used to exclude any participant with restless leg syndrome, apnea, parasomnias or other sleep disorders. On the second and third night participants are required to meet objective inclusion criteria: 2-night mean LPS of >=30 minutes with no night \<20 minutes, and on both nights TST \<=6 hours and wake after sleep onset (WASO) >30 minutes
  • Participants must be healthy / medically stable on the basis of clinical laboratory tests, medical history, vital signs, and 12-lead (ECG) performed at screening and baseline

Exclusion criteria

Exclusion Criteria:

  • Participant has current signs/symptoms of, liver or renal insufficiency; hypothyroidism or hyperthyroidism, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, or metabolic disturbances. Participants with non-insulin dependent diabetes mellitus who are adequately controlled (not on insulin) may participate in the study
  • History of epilepsy or fits or unexplained black-outs
  • abnormal values for hematology, clinical chemistry or urinalysis at screening or admission
  • Clinically significant abnormal physical and neurological examination, vital signs or 12-lead at screening or baseline
  • Smoking >=10 cigarettes/daily
  • Insomnia related to restless leg syndrome, sleep breathing disorder, narcolepsy, obstructive sleep apnea/hypopnea, central sleep apnea, sleep-related hypoventilation, circadian rhythm sleep-wake disorders, substance/medication-induced sleep disorder or parasomnias
  • Night-shift worker or significantly shifted diurnal activity pattern
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    JNJ-42847922 then Placebo

    Participants receive 2\*20 milligram (mg) tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 of period 1. After a washout period of 5 to 9 days participants will receive matching placebo from Day 1 to Day 5 of period 2.

    Drug: JNJ-42847922 · Drug: Placebo

  • Experimental
    Placebo then JNJ-42847922

    Participants will receive matching placebo from Day 1 to Day 5 of period 1. After a washout period of 5 to 9 days participants will receive 2\*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 of period 2.

    Drug: JNJ-42847922 · Drug: Placebo

Interventions

  • Participants in arm JNJ-42847922 then Placebo will receive 2\*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 1 and participants in arm Placebo then JNJ-42847922 will receive 2\*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 2.

  • DrugPlacebo

    Participants in arm JNJ-42847922 then Placebo will receive matching Placebo orally once daily from Day 1 to Day 5 in Period 2 and participants in arm Placebo then JNJ-42847922 will receive matching placebo orally once daily from Day 1 to Day 5 in Period 1.

06

What researchers measure

Primary outcomes

  1. Sleep Efficiency by Polysomnography

    The total sleep time divided by the total time in bed (that is, the number of minutes from the beginning of the Polysomnography recording to the end of the recording).

    Time frame: up to Night 5

Secondary outcomes

  1. Total Sleep Time by Polysomnography

    All of the minutes of Stages 1, 2, 3/4 Non Rapid Eye-Movement (NREM) and Rapid-Eye-Movement (REM) sleep, as measured by Polysomnography, are summed to determine the Total Sleep Time.

    Time frame: up to Night 5

  2. Wake Time After Sleep Onset by Polysomnography

    The number of minutes in the Awake stage after the onset of persistent sleep to the end of the recording.

    Time frame: up to Night 5

  3. Number of Awakenings After Persistent Sleep by Polysomnography

    Number of Awakenings is defined as the number of times after the onset of persistent sleep that there is a wake entry of at least 2 epochs in duration. Each entry must be separated by Stage 2, 3/4 NREM sleep or REM sleep in order to be counted.

    Time frame: up to Night 5

  4. Total Time Spent in Deep Sleep by Polysomnography

    Duration of slow wave sleep will be reported.

    Time frame: up to Night 5

  5. Mean Latency to Persistent Sleep by Polysomnography

    Elapsed time from the beginning of the Polysomnography recording to the onset of the first 10 minutes of continuous sleep will be measured over 2 nights and the average time to sleep will be calculated.

    Time frame: up to Night 5

  6. Leeds Sleep Evaluation Questionnaire (LSEQ) Score

    The LSEQ is a participant-reported 10-item visual analogue scale score used to rate the quality of sleep and to assess changes in sleep quality over the course of treatment.

    Time frame: up to Night 5

  7. Subjective assessment of sleep by Questionnaire

    Subjective assessment of sleep parameters will be assessed by following questions to indicate how much and how well participant slept during the past night: 1. How long did it take you to fall asleep for the first time (Mean Subjective sleep onset latency); 2. How long have you slept in total (Total sleep time); 3. How long were you awake after initial sleep onset until you finally got out of bed (Wake After Sleep Onset); 4. How often did you awake during the night (how many times); 5. How did you rate the quality of the night sleep (1= extremely bad 10 =excellent).

    Time frame: up to Night 5

  8. Next Morning Residual Effects by Bond and Lader Visual Analogue Scale

    The Bond and Lader Visual Analogue Scale consists of sixteen 100 mm visual analog scales anchored by antonyms (example, Alert-Drowsy, Lethargic-Energetic, etc). Scores will be combined to form three mood factors: alertness, calmness, and contentedness.

    Time frame: up to Night 5

  9. Next Morning Residual Effects by cognitive test battery

    Time frame: up to Night 5

  10. Next Morning Residual Effects by Karolinska Sleepiness Scale

    The KSS is a participant-reported assessment used to rate sleepiness on a scale of 1 to 9, ranging from 'extremely alert' (1) to 'very sleepy, great effort to keep awake, fighting sleep (9).

    Time frame: up to Night 5

  11. Number of Participants with Adverse Events (AEs) and Serious AEs

    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: up to Night 5

07

Study locations

5 sites
  • Hollywood, Florida, United States
  • Berlin, Germany
  • Hamburg, Germany
  • Schwerin, Germany
  • Leiden, Netherlands
08

References and documents

Publications

  • De Boer P, Drevets WC, Rofael H, van der Ark P, Kent JM, Kezic I, Parapatics S, Dorffner G, van Gerven J, Benes H, Keicher C, Jahn H, Seiden DJ, Luthringer R. A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity. J Psychopharmacol. 2018 Jun;32(6):668-677. doi: 10.1177/0269881118773745. Epub 2018 May 31. PubMed 29848147 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Dec 2015, 4 months.

Of 27 industry-sponsored phase 2 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 4 months is below that.

Counting every sponsor, half of 63 studies reached it within 17 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2015
First posted
Jun 8, 2015
StartActual
Jul 27, 2015
Primary completionActual
Dec 2, 2015
CompletionActual
Dec 2, 2015
Results delay requested
Jul 15, 2016
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02464046
Responsible party
Sponsor
First posted
Jun 8, 2015
Start date
Jul 27, 2015
Primary completion
Dec 2, 2015
Completion
Dec 2, 2015
Last update
Apr 27, 2025

Study contacts

Janssen Research & Development, LLC Clinical trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seltorexant

Start the discussion